Actively Recruiting

Age: 40Years - 85Years
All Genders
Healthy Volunteers
NCT06810635

Polyphenol Metabotypes in People With Diabetes Type 2

Led by University Hospital, Ghent · Updated on 2026-03-23

100

Participants Needed

2

Research Sites

143 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Ghent

Lead Sponsor

U

University Ghent

Collaborating Sponsor

AI-Summary

What this Trial Is About

This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).

CONDITIONS

Official Title

Polyphenol Metabotypes in People With Diabetes Type 2

Who Can Participate

Age: 40Years - 85Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants aged between 40 and 85 years
  • Age-matched individuals without diabetes
  • Body mass index (BMI) between 18.5 and 30
  • No metabolic syndrome
  • Persons diagnosed with type 2 diabetes mellitus (T2DM)
  • Clinical diagnosis of T2DM for at least 2 years
  • Stable medication use for at least 1 month
Not Eligible

You will not qualify if you...

  • Pregnancy or breastfeeding
  • Acute use of anti/pre/probiotics in the last month
  • Recent start of new drugs or dietary supplements
  • Major changes in diet
  • Major lifestyle changes
  • Having gastrointestinal diseases such as inflammatory bowel disease
  • Previous bariatric surgery
  • Other forms of diabetes including cystic fibrosis-related diabetes, MODY, or type 1 diabetes
  • Heart problems classified as NYHA 3 or 4 or previous cardiovascular events
  • Liver problems including non-alcoholic steatohepatitis (NASH) and cirrhosis
  • Lung problems such as COPD GOLD 3/4 or cystic fibrosis
  • Uncontrolled thyroid function disruption in the past 6 months
  • Use of coumarin derivatives or direct oral anticoagulant medication
  • Receiving anti-cancer treatment like chemotherapy or immunotherapy
  • Use of immunosuppressants (e.g., transplant medication)
  • Use of antiepileptic drugs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Ghent University

Ghent, East Flanders, Belgium, 9000

Not Yet Recruiting

2

Department of rehabilitation sciences - UGent

Ghent, Belgium

Actively Recruiting

Loading map...

Research Team

J

Jan Stautemas, PhD

CONTACT

P

Patrick Calders, Professor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here